Rational integration of polygenic risk scores (rips)

Active Project Grant Awarded Last action

Award ID
R01HG012262
Recipient
Awarding agency
Obligated
$10,040,365

Award facts

Assistance listing
93.172 Human Genome Research
Completion date 93% complete
Place of performance
Nashville, TN 37203, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
There has been extraordinary growth in new techniques to predict common, complex disease based on polygenic risk scores (PRS). Without an understanding grounded in evidence, IT is unlikely that the clinical use of PRS will propagate from highly specialized applications and environments to become adopted more broadly and provide greater benefit to the US population. Critical challenges include: 1) understanding the impact of clinical PRS for multiple diseases on long-term patient outcomes, 2) identifying risk thresholds for return of results that optimize patient outcomes and provide cost-effective care, 3) understanding how PRS performance across diverse populations may affect existing disparities and subsequent patient outcomes. We propose to address these challenges using decision analytic modeling and by building on our extensive work in this area to create a novel framework capable of assessing prss in the context of monogenic and clinical risks. We have already created clinical-economic models to project lifetime clinical impact and cost-effectiveness for population-level genomic screening with return of monogenic disease risks associated with three CDC tier 1 conditions: hereditary breast and ovarian cancer, lynch syndrome, and familial hyperlipidemia. As part of this proposal, titled rational integration of polygenic risk scores (rips), we will create models to assess the clinical outcomes and economic value of population screening using PRS in real- world settings and applied to large and diverse populations. The aims of the proposal include 1) to evaluate published and real-world evidence on the clinical value of adding PRS to inform comprehensive genomic risk assessment; 2) to understand the impact of PRS performance and return risk thresholds on incremental clinical benefit and cost effectiveness for breast cancer, atherosclerotic cardiovascular disease, and colorectal cancer, and 3) to develop research priorities for the equitable development and implementation of PRS across underserved and underrepresented populations.

Transactions

Action Obligated Date
Amendment Rational integration of polygenic risk scores (rips) - there has been extraordinary growth in new techniques to predict common, complex disease based on… $863,677
Amendment $87,881
Amendment $790,943
Amendment $790,943
Amendment $73,791
Amendment $73,791
Amendment $73,791
Amendment $830,145
Amendment $830,145
Amendment $830,145
Amendment $830,145
Amendment $955,275
Amendment $955,275
Amendment $955,275
Amendment $99,922
Amendment $99,922
Original award $899,299
Show all 17

Subawards

Subrecipient Amount Awarded
Geisinger Clinic Rational Integration of Polygenic Risk Scores (RIPS) $287,889
University Of Washington $287,892
Geisinger Clinic $263,647
University Of Washington $263,648
University Of Washington $296,182
Geisinger Clinic $336,242

Quick answers

Who received award R01HG012262?

R01HG012262 was awarded to Vanderbilt University Medical Center by National Human Genome Research Institute (National Institutes of Health) on March 10, 2022.

How much is award R01HG012262 worth?

$10,040,365 has been obligated on R01HG012262.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login